CaliberCos Inc. (Nasdaq: CWD), headquartered in Scottsdale, Arizona, received a formal deficiency notice from Nasdaq on August 21, 2026, after the company's Class A common stock closed below $1.00 per share for 33 consecutive business days. The notice carries no immediate consequence for listing status, but it starts a countdown the company's own filing acknowledges may not end in its favor.
The compliance window and what it demands
The path back is narrow but defined. Nasdaq's rules afford CaliberCos a 180-calendar day grace period through February 17, 2027. To satisfy Listing Rule 5550(a)(2), the stock needs to close at or above $1.00 per share for at least ten consecutive business days before that date. The stock's 33-day run below the floor suggests compliance isn't happening organically.
If the company misses that window, a second 180-day period becomes available, but only conditionally. Caliber would need to meet the criteria for initial listing on the Nasdaq Capital Market, satisfy the continued listing requirement for market value of publicly held shares, and commit in writing to curing the deficiency, through a reverse stock split if necessary. That last point matters. A reverse split closes the compliance gap on paper. It does nothing about what drove the stock below a dollar in the first place.
The counterargument
The counterargument for patience is procedural. Nasdaq's rules build in multiple checkpoints before a stock actually comes off the exchange. Even after a staff delisting notice, CaliberCos can request a hearing before the Nasdaq Hearings Panel, and that request would stay any delisting action while the process runs. The stock could remain on Nasdaq well past February 2027 if the company pursues every available step.
On balance, the filing's own language hedges: there is no assurance the company would be successful in its efforts to maintain the Nasdaq listing. The line to watch is the bid price over the coming weeks. If CaliberCos cannot close above $1.00 for ten consecutive business days before February 17, 2027, the company's stated fallback is the OTC Markets Group. The 8-K, signed by Chairman and Chief Executive Officer John C. Loeffler, II, was filed on August 26, 2026.